ID   A2780-DR
AC   CVCL_EG64
DR   cancercelllines; CVCL_EG64
DR   PRIDE; PXD001176
DR   PRIDE; PXD003252
DR   Wikidata; Q54606564
RX   PubMed=25096996;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Omics: Proteome analysis.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 11
//
RX   PubMed=25096996; DOI=10.1074/mcp.M113.033217;
RA   Jin L.-X., Huo Y., Zheng Z.-G., Jiang X.-Y., Deng H.-Y., Chen Y.-L.,
RA   Lian Q.-Q., Ge R.-S., Deng H.-T.;
RT   "Down-regulation of Ras-related protein Rab 5C-dependent endocytosis
RT   and glycolysis in cisplatin-resistant ovarian cancer cell lines.";
RL   Mol. Cell. Proteomics 13:3138-3151(2014).
//